Compare
NextCure, Inc. vs Actinium Pharmaceuticals, Inc. vs Vistagen Therapeutics, Inc. vs Akari Therapeutics Plc
| Latest fiscal year | NextCure, Inc. NXTC | Actinium Pharmaceuticals, Inc. ATNM | Vistagen Therapeutics, Inc. VTGN | Akari Therapeutics Plc AKTX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2026-03-31 | 2025-12-31 |
| Revenue | n/a | $90.0K | $1.27M | n/a |
| Revenue growth (YoY) | n/a | n/a | +161.1% | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/m | n/m | n/a |
| Net margin | n/a | n/m | n/m | n/a |
| Net income | -$55.84M | -$33.89M | -$69.69M | -$17.30M |
| EPS (Diluted) | -$19.65 | -$1.09 | -$1.83 | $0.00 |
| Operating cash flow | -$49.61M | -$24.58M | -$66.44M | -$10.57M |
| Free cash flow | n/a | -$24.68M | n/a | n/a |
| Cash & equivalents | $25.98M | $48.00M | $30.79M | $0 |
| Total assets | $50.18M | $51.77M | $48.56M | $47.89M |
| Total liabilities | $15.24M | $43.94M | $13.04M | $19.56M |
| Shareholders' equity | $34.94M | $7.83M | $35.52M | $28.33M |
| Return on year-end equity | -159.8% | -432.6% | -196.2% | -61.1% |
| Shares outstanding | 3.51M | 31.20M | n/a | 90.54B |
Revenue, most recent five fiscal years
| Fiscal year | NextCure, Inc. | Actinium Pharmaceuticals, Inc. | Vistagen Therapeutics, Inc. | Akari Therapeutics Plc |
|---|---|---|---|---|
| Latest | $22.38M Ended 2020-12-31 | $90.0K Ended 2025-12-31 | $1.27M Ended 2026-03-31 | n/a |
| 1 year earlier | $6.35M Ended 2019-12-31 | n/a | $486.0K Ended 2025-03-31 | n/a |
| 2 years earlier | n/a | $81.0K Ended 2023-12-31 | $1.06M Ended 2024-03-31 | n/a |
| 3 years earlier | n/a | $1.03M Ended 2022-12-31 | n/a | n/a |
| 4 years earlier | n/a | $1.14M Ended 2021-12-31 | $1.11M Ended 2022-03-31 | n/a |